Merck Out-Licenses Gene Therapy Assets To FKD Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.